排序方式: 共有76条查询结果,搜索用时 31 毫秒
1.
2.
3.
Quique Bassat Bernhards Ogutu Abdoulaye Djimde Kirstin Stricker Kamal Hamed 《Antimicrobial agents and chemotherapy》2015,59(8):4366-4374
Specially created pediatric formulations have the potential to improve the acceptability, effectiveness, and accuracy of dosing of artemisinin-based combination therapy (ACT) in young children, a patient group that is inherently vulnerable to malaria. Artemether-lumefantrine (AL) Dispersible is a pediatric formulation of AL that is specifically tailored for the treatment of children with uncomplicated Plasmodium falciparum malaria, offering benefits relating to efficacy, convenience and acceptance, accuracy of dosing, safety, sterility, stability, and a pharmacokinetic profile and bioequivalence similar to those of crushed and intact AL tablets. However, despite being the first pediatric antimalarial to meet World Health Organization (WHO) specifications for use in infants and children who are ≥5 kg in body weight and its inclusion in WHO Guidelines, there are few publications that focus on AL Dispersible. Based on a systematic review of the recent literature, this paper provides a comprehensive overview of the clinical experience with AL Dispersible to date. A randomized, phase 3 study that compared the efficacy and safety of AL Dispersible to those of crushed AL tablets in 899 African children reported high PCR-corrected cure rates at day 28 (97.8% and 98.5% for AL Dispersible and crushed tablets, respectively), and the results of several subanalyses of these data indicate that this activity is observed regardless of patient weight, food intake, and maximum plasma concentrations of artemether or its active metabolite, dihydroartemisinin. These and other clinical data support the continued use of pediatric antimalarial formulations in all children <5 years of age with uncomplicated malaria when accompanied by continued monitoring for the emergence of resistance. 相似文献
4.
Michael Marks Pere Millat-Martinez Dan Ouchi Chrissy h Roberts Andrea Alemany Marc Corbacho-Monné Maria Ubals Aurelio Tobias Cristian Tebé Ester Ballana Quique Bassat Bàrbara Baro Martí Vall-Mayans Camila G-Beiras Nuria Prat Jordi Ara Bonaventura Clotet Oriol Mitjà 《The Lancet infectious diseases》2021,21(5):629-636
5.
6.
Agnandji ST Lell B Soulanoudjingar SS Fernandes JF Abossolo BP Conzelmann C Methogo BG Doucka Y Flamen A Mordmüller B Issifou S Kremsner PG Sacarlal J Aide P Lanaspa M Aponte JJ Nhamuave A Quelhas D Bassat Q Mandjate S Macete E Alonso P Abdulla S Salim N Juma O Shomari M Shubis K Machera F Hamad AS Minja R Mtoro A Sykes A Ahmed S Urassa AM Ali AM Mwangoka G Tanner M Tinto H D'Alessandro U Sorgho H Valea I Tahita MC Kaboré W Ouédraogo S Sandrine Y Guiguemdé RT Ouédraogo JB Hamel MJ Kariuki S 《The New England journal of medicine》2011,365(20):1863-1875
7.
8.
9.
10.
INTRODUCTION: Malaria continues to represent a huge global health burden on the most vulnerable populations. The Intermittent Preventive Treatment (IPT) strategy has been shown to be an efficacious intervention in preventing most of the deleterious effects of malaria in pregnant women and infants. Yet, the effectiveness of the IPT strategy may be impaired by the increasing resistance to sulfadoxine-pyrimethamine (SP), and the scarcity of alternative antimalarial drugs. AREAS COVERED: This review examines all the available information on IPT, in an aim to provide the scientific community with a framework to understand the benefits and limitations of this malaria control strategy. It includes the understanding of the historical background of the IPT strategy, the drug's mechanisms of actions, updated information on current available evidence, the implications of drug resistance and choice of alternative drugs, and a comprehensive discussion on the perspectives of IPT for malaria control in pregnant women and infants. EXPERT OPINION: IPT in pregnancy and infants is a cost-effective strategy that can contribute significantly to the control of malaria in endemic areas. Monitoring its effectiveness will allow tracking of progress, evaluation of the adequacy of currently used drugs and will highlight the eventual need for new therapies or alternative interventions. 相似文献